Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Q2 2017 Results Earnings Conference Call August 10, 2017 10:00 AM ET
John Gandolfo - CFO
Carl O'Connell - CEO
Greetings, and welcome to the Xtant Medical Second Quarter 2017 Results Conference Call. At this all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded.
It is would now just turn the conference over to John Gandolfo, Chief Financial Officer. Thank you, please go ahead.
Good morning, and thank you for joining us today for the Xtant Medical second quarter 2017 results conference earnings call. Joining me today will be Carl O'Connell, Chief Executive Officer for Xtent. Yesterday afternoon, Xtant issued a press release announcing second quarter 2017 financial results.
Today's call is being webcast and will be posted on the company's website for playback. We expect the duration of the call to be approximately 30 minutes.
During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intends and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of our most recent annual report on Form 10-K.
In addition, any unaudited or pro forma financial information is preliminary and does not purport to project the future financial position or operating results of the company.
Actual results may differ materially. For the benefit of those of you who may be listening to the replay, this call was held and recorded on Thursday, August 10, 2017, at approximately 10 a.m. Eastern Time. Since then, the company may have made additional announcements related to the topics discussed herein. Please reference the company's most recent press releases and current filings with the SEC. The company declines any obligation to update these forward-looking statements, except as required by applicable law.
With that, I would like to turn the call over to Carl.
Thank you, John. I’ll begin by highlighting some of the company's achievement this quarter and provide updates regarding our focus on achieving operating excellence in 2017. John will provide additional detail regarding our quarterly results. For legal advisement, we are not able to field questions following today's call as we remain in negotiations with the senior debt lender to restructure the company's debts and although we remain hopeful that these negotiations will be successful, there are no assurances, they will be successful.
In addition, as previously announced the July 15, 2017 interest payment due under the company's various convertible promissory notes were deffered by the holders of such notes until August 15, 2017. The company is currently negotiating amendments to the indenture dated July 31, 2015 and to the additional convertible promissory notes held by ROS Acquisition Offshore LP and Orbimed Royalty Opportunities II LP to extend the date for the payment of such interest.
No assurance can be given that the company will be successful in obtaining appropriate amendments by August 15, 2017 or at all. Or that if the company becomes in default on to the convertible promising notes on August, 15 2017 that the holders thereof will waive such a default in subsequent amendments. We appreciate your ongoing support during the quite period.
With that I'd like to jump in to the review of the second quarter success and our momentum into the second half of 2017.
In May, we announced the delay to our debt financing by over met of 16 million with proceeds used to pay-off on outstanding balance of $9 million under the account receivable credit facility with Silicon Valley Bank and the remaining to support restructuring initiatives and we use for general working capital purposes.
In conjunction with the financing commitments we entered into an amendment with Aurora Management Partners engaging David Baker and Wayne Tanner to serve as restructuring officers and direct the company's financial and operating restructuring efforts.
Their focus has been on improving the day to day financial operations of the organization and they have been successfully implementing improved process supporting a successful trajectory for profitability of the organization. We look forward to continue our relationship with David and Wayne and the Aurora Management Team as we move into a new phase of our business.
Last night, we issued a press release announcing $21.4 million in revenue for the second quarter, which was flat in comparison to the second quarter of 2016. Despite flat revenue growth this last quarter we are pleased with our progress given the amount of sales force and operational restructuring activities we've implemented thus far. We anticipated minor disruption to our revenue stream which we expect will stabilize as we exit this quarter.
For comparison purposes, we had one less selling day in the quarter in comparison to the second quarter of 2016. That would have led to an increase of 1.5% over the prior year if looking at our average revenue per day of second quarter of 2017.
Our EBITDA performance for the quarter was a loss of approximately $2.1 million compared to a gain of $252,973 for the same period last year. Our EBITDA loss is mostly due to a lower gross margin for the quarter and increased sales and marketing expenses. The lower gross margin was due to the reduction of fixed fixation revenue and corresponding lower gross margin on these revenues, as well as charges for excessive wear and tear on fixation instruments and the right-off of biologics finished goods inventory which we expect to expire in the near future.
The increased sales and marketing expenses were due to more revenue being derived from distributors with higher contracted commission rates. One of our major areas of focus for the second half of 2017 will be on maximizing the company's gross profits and reducing our cost of selling and be more in line with industry standards so we can have a solid platform to grow in 2016 and beyond.
As stated on earlier earnings calls my leadership team will continue to actualize merger synergies and further integration efforts for the company. Such as combining our quality and regulatory functions to operate under one corporate entity at the [indiscernible] level. Additional activity such as merging our customer care and invoicing functions and consolidating our ERP system into unified platform have also taken place.
These efficiencies with a focus on repurposing have also helped to optimize operational functions and drive overall annual cost savings of approximately $4.2 million. Expense for headcount reductions approximately $850,000 which was mostly paid-out in the first half of the year are projected to be complete by the end of Q3. These activities will ultimately contribute to our EBITDA and bolster financial performance in the second half of 2017 and beyond.
As we continue to focus on operational efficiencies we do expect significant change in transition for this year within our organization. We're being mindful to minimize and mitigate disruption for our employees, partners and vendors, enabling us to continue our transformation towards a more successful and profitable company which will deliver greater shareholder value for years to come.
Important to mention our employees are one of our valuable assets our organization has and we will continue to invest in programs for them and nurture a culture that rewards initiative and great performance. To that end our management has implemented an employee satisfaction program and will measure the performance and success of these programs going forward.
Through this transition process an implementation of changes for continuous improvement we've had numerous achievements that will help us in building momentum moving at that third and fourth quarter of 2017. We're focusing on strengthening key foundational elements of the business in our effort to position the company to achieve operational success. The three main initiatives previously emphasized are, improving our asset utilization, improving our strategic mission ambition to position for market leadership and optimizing our sales channels.
Within asset utilization we've made major strides over the last year especially in supply chain management with our fixation business. Our teams led by recently promoted VP of Operations in Hardware R&D, Anthony DeFalco and our Director of Commercial Operations Shea Vincent are well ahead of their cost saving goals and in inventory reduction and kit utilization and optimization.
We continue to build our portfolio, in May we announced licensing agreement with Sites Medical for utilization for their best in class porous titanium scaffold. As these parts are currently in development we will speak about the opportunity this partnership presents later in the year. This is strategic initiatives designed to strength our position in regenerative care by placing focus on technologies that will further integrate our hardware and biologics portfolio.
Another example of this strategy is the additional FDA clearance we announced yesterday for Calix-C product line extension. Not only does this new clearance include larger footprints for addressing the needs for more patients and need of surgical fusions it also includes the indication for use with Allografts, such as our proprietary OsteoSync [ph] scaffold, 3Demin and OsteoVive.
In improving our leadership positive in regenerative care, we again achieved record growth with our OsteoVive viable cell allograft product with 92% growth over the first quarter this year generating approximately 478,000 in revenue, this is a line that we introduced through an alpha launch in June 2016 and we anticipate this growth trend will continue.
We’ve also recognized continued upward trends with our 3Demin family of demineralized cortical fiber technology with year-over-year growth of 48% to $1.5 million in Q2 of this year. Overall, biologics revenue increased 21% year-over-year reaching $12.5 million this quarter.
This growth has mostly been driven by legacy hardware distributors pulling through more biologics in alignment with our portfolio selling initiatives. In order to view of the performance of our top 10 distributors the average growth achieved per agency was 31% year-over-year. 17% of our distributor network is focused on distributing our hardware and biologics lines and are responsible for generating over 50% of our revenue in the first half of the year.
Our sales team under the leadership of Chris Valois continues to cascade this level of success across our distributor network. Our sales optimization programs internationally we've achieved 17% growth year-over-year driven mostly by our European and Latin American distributor partners. We expect our international revenue to continue our growth trajectory throughout the remainder of the year.
For our U.S. sales optimization program, we continue to make great improvements and move towards the performance driven organization. About three season sales executives each with extensive and successful experience in spine and orthopedic sales, and have managed both independent and direct sales channels.
Further to sales management improvements we are strengthening the existing distribution channel to distribute and focus on additional elements of the product portfolio while targeting accounts under contractual access. And building upon the efforts of the first half of the year to establish a sustainable sales foundation we will be looking to add a team of regenerative care specialists as direct sales employees to service new accounts in large metropolitan locations with contractual opportunity. This would-be part of a hybrid sales model designed to provide additional support to our distribution channel especially as we look to launch new products in the regenerative technology market.
Additionally in this effort we announced the expansion of our national accounts team on our last earnings call. They have aggressively persuaded contract opportunities with integrated delivery networks and health systems, resulting in an additional of 16 new contracts in the second quarter for both hardware and biologics opening up an additional 250 facilities for potential incremental revenue growth. I continue to believe that we have the best national accounts team in the industry. I am excited about the contractual position of the company which will serve to support our future U.S. sales strategies.
I would now like to turn the call over to John to discuss the financial performance on the second quarter. John?
Thank you, Carl. Slide Number 8 outlines selected profit and loss statement information for the company for the three months and six months ended June 30, 2017, compared to the same information for the comparable period of the prior year. Consolidated total revenues for the three months ended June 30, 2017, was approximately $21.4 million compared to $21.5 million of revenue for the same period of 2016.
For the six months ended June 30, 2017 revenue was approximately $43.5 million, a 2.5% increase compared to $42.4 million reported for the first six months of 2016. Consolidated gross profit for the second quarter of 2017 was $13.5 million or 63.2% of revenue and this compares to gross profit of $14.7 million or 68.5% of revenues for the second quarter of 2016. As Carl previously mentioned the gross margin contraction is primarily the result of the decrease in fixation revenues and a corresponding lower gross margin on fixation products.
In addition, the company incurred a charge of approximately $304,000 for our excessive wear and tear on fixation instrument and the $159,000 for biologics inventory which was about to expire.
For the six months ended June 30, 2017 gross profit was $29.1 million or 66.8% of revenue compared to $28.8 million or 67.9% of revenues in the prior year. The slight decrease in gross margin was attributable to the lower fixation revenue and lower fixation gross margin, the previously mentioned charges for fixation instruments and biologics inventory which was offset by an increase in biologics processing supplies which were capitalized in the inventory.
The company reported a second quarter 2017 loss from operations of $4.7 million compared to a lowest from operations of $2.1 million in the second quarter of 2016. The increase operating loss was result of the previously noted lower gross profit and increase in sales and marketing expenses of $717,000 due launch to higher commission payments and increased G&A expenses of approximately $627,000 which includes approximately $214,000 of contributions to the company's employee benefit plan, additional insurance expand of approximately of $142,000 as well as additional professional fees.
For the six-month ended June 30, 2017 loss from operations of $6.7 million compared to an operating loss of $4.5 million. The increase loss from operations was due to the increase G&A expenses previously noted and an increase of $1.2 million in sales and marketing expense associated with more revenues bring derived from distributors who had higher contracted sales commission rate.
Net loss for the three months ended June 30, 2017, was $9.7 million compared to a net loss of $4.5 million in the second quarter of 2016. The second quarter 2017 net loss figure includes approximately $1.5 million of professional fees associated with the company's restructuring and approximately $3.3 million of quarterly interest expense. For the six-month ended June 30, 2017, the company reported a net loss of approximately $14.9 million compared to a net loss $10.1 million in the prior year.
The company defines EBITDA as earnings before interest, taxes, depreciation and amortization, as net income loss from operations before depreciation, amortization, impairment charges, nonrecurring expenses and noncash stock-based compensation. Consolidated EBITDA for the second quarter of 2017 was a loss of $2.1 million compared to consolidated EBITDA gain of $253,000 for the same period during 2016.
The decrease in EBITDA was a largely that result of lower quarterly gross profit and increased sales and marketing expense between the two periods which we noted previously. As Carl mentioned the company will be placing a large effort throughout 2017 in order to get the company to maximize the EBITDA and operating cash flow in future periods.
For the six months ended June 2017 the company reported an EBITDA loss of $1.6 million compared to an EBITDA gain of $27,000 in the first six months of 2016.
Turning now to our balance sheet. Total assets as of June 30, 2017, included approximately $1.7 million of cash and cash equivalents, $15.8 million of net accounts receivable and $24.9 million of inventory.
As of today, the company has approximately $4.2 million of funds available to draw down on its delayed draw term debt with Orbimed. As we announced previously under the terms of the agreement the availability of these funds at the discretion of Orbimed.
Total liabilities include approximately $70.7 million of convertible debt and $63.3 million of long term debt due to Orbimed devices.
Now I would like to turn the call back over to Carl.
Thank you, John. My leadership team and I are optimistic for the remainder of 2017 and beyond. We're energized and committed to making the necessary changes in every aspect of the business to transform the company. We continue to focus on restructuring on those specific activities related to operational excellence creating more efficiencies ultimately establishing the right profitable and performance structure allowing us to prepare for growth for 2018. We believe we are creating value for our shareholders by driving leading edge regenerative technologies in the spine industry while creating an increasingly profitable and sustainable revenue growth model.
We would like to thank our shareholders and our stakeholders for your continued support and look forward to providing you with an update on our restructuring efforts since discussions was Orbimed are finalized. Thank you.
Thank you. This does conclude today's teleconference. You may disconnect your lines at this time, and thank you for your participation.
End of Q&A